Philip Bacidore, DO
Cardiovascular Disease · Vincennes, INNPI 1891793634
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 123 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 16.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $667 and has fallen 57.8% since, to $281 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in IN, where the typical reported total is $2,452.
Across 123 payments — averaging $17.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$348
- Actelion Pharmaceuticals US, Inc.$284
- AstraZeneca$253
- Novartis$200
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$179
- Amgen$162
- plus $709 from 22 others
What the payments were for
- Food & beverage$2,134100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 23 | $348 |
| Actelion Pharmaceuticals US, Inc. | 14 | $284 |
| AstraZeneca | 13 | $253 |
| Novartis | 12 | $200 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $179 |
| Amgen | 10 | $162 |
| Boehringer Ingelheim | 5 | $79 |
| Novo Nordisk | 4 | $76 |
| Pfizer | 4 | $60 |
| Abiomed | 2 | $60 |
| GSK | 3 | $45 |
| E.r. Squibb & Sons, L.L.C. | 2 | $45 |
| Philips North America LLC | 3 | $40 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $34 |
| Pulmonx Corporation | 1 | $32 |
| Johnson & Johnson | 2 | $29 |
| Grifols USA, LLC | 2 | $24 |
| Abbott | 1 | $23 |
| Sanofi | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $19 |
| United Therapeutics Corporation | 1 | $18 |
| Lexicon Pharmaceuticals, Inc. | 1 | $18 |
| Preventice Services, LLC | 1 | $17 |
| Inspire Medical Systems, Inc. | 1 | $14 |
| Bayer | 1 | $13 |
| Chiesi USA, Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Baxter Healthcare | 1 | $13 |
How this compares
$2,134 in reported general payments places this provider in the 45th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 385 | $375,909 |
| XareltoRivaroxaban | 221 | $226,343 |
| EntrestoSacubitril/Valsartan | 139 | $159,754 |
| Repatha SureclickEvolocumab | 67 | $58,983 |
| JardianceEmpagliflozin | 39 | $40,580 |
| FarxigaDapagliflozin Propanediol | 30 | $32,450 |
| BrilintaTicagrelor | 33 | $31,270 |
| Praluent PenAlirocumab | 24 | $13,583 |
| Metoprolol Succinate | 836 | $9,311 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 220 | $5,775 |
| Atorvastatin Calcium | 458 | $3,561 |
| Propafenone Hcl | 69 | $3,354 |
| ClopidogrelClopidogrel Bisulfate | 294 | $3,192 |
| Amlodipine Besylate | 622 | $2,987 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 246 | $2,559 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $60 | $375,909385 claims |
| Johnson & JohnsonXarelto | $29 | $226,343221 claims |
| NovartisEntresto | $200 | $159,754139 claims |
| AstraZenecaFarxiga, Brilinta | $253 | $63,72063 claims |
| Boehringer IngelheimJardiance | $79 | $40,58039 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 408 cardiovascular disease providers in Indiana.
Other cardiovascular disease in Vincennes
- John MillerIndianapolis$354K
- David KovacichIndianapolis$327K
- Wai LeeElkhart$321K
- Anas SafadiHobart$295K
- Lawrence RinkBloomington$280K
- Vijay RaoIndianapolis$247K
- Steven SteinhublLafayette$247K
- Atul ChughIndianapolis$242K
- James TrippiIndianapolis$239K
- Christopher HealyIndianapolis$209K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.